Literature DB >> 7628979

Glycylcyclines: a new generation of tetracyclines.

F T Tally1, G A Ellestad, R T Testa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628979     DOI: 10.1093/jac/35.4.449

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  13 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline.

Authors:  Ad C Fluit; Alice Florijn; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Antibacterial agents that inhibit two-component signal transduction systems.

Authors:  J F Barrett; R M Goldschmidt; L E Lawrence; B Foleno; R Chen; J P Demers; S Johnson; R Kanojia; J Fernandez; J Bernstein; L Licata; A Donetz; S Huang; D J Hlasta; M J Macielag; K Ohemeng; R Frechette; M B Frosco; D H Klaubert; J M Whiteley; L Wang; J A Hoch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 4.  The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.

Authors:  I Chopra; J Hodgson; B Metcalf; G Poste
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

Authors:  C Jamjian; D J Biedenbach; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria.

Authors:  B A Brown; R J Wallace; G Onyi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 9.  The glycylcyclines: a comparative review with the tetracyclines.

Authors:  George G Zhanel; Kristen Homenuik; Kim Nichol; Ayman Noreddin; Lavern Vercaigne; John Embil; Alfred Gin; James A Karlowsky; Daryl J Hoban
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.

Authors:  Mary L Townsend; Melanie W Pound; Richard H Drew
Journal:  Infect Drug Resist       Date:  2011-03-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.